Buscar
01/09/2025
Bimekizumab achievement of 'super response' using a previously published definition in moderate to severe plaque psoriasis: Results from four phase 3/3b trials
Lebwohl, M, Langley, RG, Strober, B, Thaçi, D, Armstrong, A, Gordon, KB, Puig, L, Davies, O, Peterson, L, Davis, L, Warren, RB. Bimekizumab achievement of 'super response' using a previously published definition in moderate to severe plaque psoriasis: Results from four phase 3/3b trials. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2025; 93(3)DOI:. PMID:. IF:11.800(Q1/1D).
01/07/2025
Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter Study
Ceravalls, J, Giménez-Arnau, AM, Exposito-Serrano, V, Chico, NF, Moya, AL, Bielsa, I, Ribó, P, Mascaró-Hereza, B, Bonfill-Orti, M, Spertino, J, Serra, E, Baliu-Piqué, C, Melé-Ninot, G. Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter Study. Actas Dermo-Sifiliograficas. 2025; 116(7)DOI:10.1016/j.ad.2024.08.014. PMID:. IF:(Q/D).
01/06/2025
Surgical Approach to Hidradenitis Suppurativa
Mateu-Arrom, L, Puig, L, Vilarrasa, E. Surgical Approach to Hidradenitis Suppurativa. Actas Dermo-Sifiliograficas. 2025; 116(6)DOI:10.1016/j.ad.2024.10.061. PMID:40185225. IF:(Q/D).
01/06/2025
Bimekizumab clinical efficacy in impactful body regions and health-related quality of life in patients with plaque psoriasis: Data from four phase 3/3b comparator-controlled trial periods
Smith, A, Armstrong, AW, Elewski, B, Rich, P, Augustin, M, Carrascosa, JM, Vender, R, Lambert, J, Pinto, JML, Hoepken, B, Kavanagh, S, Puig, L. Bimekizumab clinical efficacy in impactful body regions and health-related quality of life in patients with plaque psoriasis: Data from four phase 3/3b comparator-controlled trial periods. AUSTRALASIAN JOURNAL OF DERMATOLOGY. 2025; 66DOI:. PMID:. IF:1.800(Q3/6D).